Cue Biopharma (CUE) Capital Expenditures (2017 - 2025)
Cue Biopharma (CUE) posted Capital Expenditures of $27000.0 for Q2 2025, down 82.0% sequentially from $150000.0 in Q1 2025, and up 170.0% YoY from $10000.0 in Q2 2024.
Cue Biopharma (CUE) Capital Expenditures (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Capital Expenditures for 8 years, with the latest figure at $27000.0 in Q2 2025.
- Quarterly Capital Expenditures rose 170.0% year-over-year to $27000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $177000.0 (up 168.18% YoY) and the FY2025 annual result came in at $177000.0, up 168.18% from the prior year.
- Capital Expenditures fell to $27000.0 in Q2 2025 per CUE's latest filing, from $150000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $648000.0 in Q1 2021 and troughed at -$1000.0 in Q3 2024.
- A 4-year average of $94788.5 and a median of $27000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2022: Capital Expenditures plunged 99.96% in 2021, then soared 2464.1% in 2022.
- Over 4 years, Capital Expenditures stood at $39.0 in 2021, then jumped by 2464.1% to $1000.0 in 2022, then surged by 100.0% to $2000.0 in 2024, then jumped by 1250.0% to $27000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $27000.0, $150000.0, and $2000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | 78,000.00 |
| Sep 30, 2022 | 78,000.00 |
| Jun 30, 2022 | 65,000.00 |
| Jun 30, 2022 | 65,000.00 |
| Mar 31, 2022 | 27,000.00 |
| Mar 31, 2022 | 27,000.00 |